Vanguard Russell 2000 ETF
Does Accelerate Diagnostics’ Financial Performance Bode Well?
The net sales of Accelerate Diagnostics (AXDX) increased from $24,000 in 3Q16 to $828,000 in 3Q17.
Decoding the Advisory Board’s Net Profit Margins in 2017
In 1Q17, the Advisory Board (ABCO) reported adjusted EBITDA of ~$45 million, which was higher than its guidance of $37 million–$42 million.
Word on the Street: What Analysts Think about SHAK after 1Q16
SHAK’s better-than-expected 1Q16 results led analysts to increase their consensus median price target for the next 12 months from $40.4 to $41.3.